Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“In this subset of patients, maintenance therapy with proteasome inhibitors alone or in combination with lenalidomide seems to be more effective than single-agent lenalidomide34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“Patients with high-risk cytogenetic features might be the only exception, although they do derive a progression-free survival (PFS) benefit34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“The most worrisome adverse effect observed in studies of lenalidomide maintenance therapy is an up to six-fold increase in the risk of second primary malignancies, in particular, MDS and acute myeloid leukaemia (AML): 5.3% versus 0.8% with placebo or observation34.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Cited by
Items 501–600 of 793
China's potential role in humanitarian assistance
Binder, A., & Conrad, B. (2009) · Cited by 9
Isoda, A., Murayama, K., Ito, S., Kohara, Y., Iino, M., Miyazawa, Y., Matsumoto, M., Handa, H., Imai, Y., Ishiguro, T., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2448-9 · Cited by 6
Murakami, H., Kasamatsu, T., Murakami, J., Kiguchi, T., Kanematsu, T., Ogawa, D., Takamatsu, H., Handa, H., Ozaki, S., Miki, H., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02607-z · Cited by 7
Improved understanding of disease biology and treatment
Miguel, J. F. S., & Kantarjian, H. M. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.216 · Cited by 6
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
Kumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N. S., Singh, A., Parker, T. L., Green, M., Thertulien, R., Parsons, B. M., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600157 · Cited by 7
Self-citationBarilà, G., Quaglia, F. M., Furlan, A., Pescosta, N., Bonalumi, A., Marcon, C., Pascarella, A., Tinelli, M., March, E. D., Liço, A., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05443-8 · Cited by 5
Lee, J. H., Choi, J., Min, C., Park, S., Jo, J., Lee, Y. J., Kim, J. S., Eom, H., Jung, J., Moon, J. H., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285534 · Cited by 7
Self-citationKhan, S., Bergstrom, D. J., Côté, J. A., Kotb, R. R., LeBlanc, R., Louzada, M., Mian, H. S., Othman, I., Colasurdo, G., & Visram, A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.012 · Cited by 6
Hungria, V., Gaiolla, R. D., Gálvez, K., Remaggi, G., Schutz, N. P., Bittencourt, R., Maiolino, Â., Quintero, G., Cugliari, M. S., Braga, W. M. T., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013838 · Cited by 6
Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma
Richter, J. R., & Jagannath, S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.09.003 · Cited by 6
“Rawstron et al32 showed that each log reduction in disease detection yielded an approximate 1-year improvement in OS.”
InfluentialAlahmadi, M. D., Masih‐Khan, E., Atenafu, E. G., Chen, C. I., Kukreti, V., Tiedemann, R. E., Trudel, S., & Reece, D. E. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.007 · Cited by 5
Self-citationMilrod, C. J., Mann, M., Blevins, F., Hughes, D., Patel, P., Li, K. Y., Lerner, A., Sanchorawala, V., & Sloan, J. M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103644 · Cited by 5
Voorhees, P. M., Suman, V. J., Efebera, Y. A., Raje, N. S., Tuchman, S. A., Valdes, C. R., Laubach, J. P., Bova‐Solem, M., Carlisle, D., Usmani, S. Z., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013623 · Cited by 9
“7-11 Thus, the utility of LEN-based therapies at fi rst relapse is limited.”
Mondello, P., Pitini, V. V., Barresi, V., Brea, E. J., Mirto, C. D., Arrigo, C., Cuzzocrea, S., & Mian, M. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0030-1 · Cited by 6
“Lenalidomide has demonstrated to be highly active in nonGCB [29] as well as in MM [22].”
BackgroundNovel combination approaches for myeloma
Lonial, S., & Nooka, A. K. (2015) · Hematology · doi:10.1182/asheducation-2015.1.286 · Cited by 5
Takemori, N., Imai, G., Hoshino, K., Ooi, A., & Kojima, M. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-017-1550-6 · Cited by 5
“Len has generally been used in combination with Dex for treating refractory and relapsed MM [1], newly diagnosed MM [2, 3], and transplant-ineligible MM [4].”
BackgroundMurray, S., Mohty, M., Péloquin, S., van de Donk, N. W. C. J., Leitão, S., Labbé, S., West, S., Hofstädter-Thalmann, E., & Sonneveld, P. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000033 · Cited by 7
Lu, J., & Chen, W. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0052 · Cited by 5
Reducing infection-related morbidity and mortality in patients with myeloma
Ramasamy, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30649-7 · Cited by 5
Hradská, K., Kaščák, M., Hájek, R., & Jelínek, T. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1733405 · Cited by 5
“The hypothesis was that the anti-PD-1 mAb might enhance the anti-myeloma effect of lenalidomide and dexamthasone which had been a standard of care in first line therapy [55].”
BackgroundBalitsky, A. K., Karkar, A., McCurdy, A. B. R., Rochwerg, B. N., & Mian, H. S. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13496 · Cited by 5
Ibarra, G., Peña, M., Abril, L., Senín, A., Maluquer, C., Clapés, V., Baca, C., Bustamante, G., Sureda, A. M., & Oriol, A. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13643 · Cited by 6
Self-citationMcCurdy, A. B. R., Venner, C. P., Masih‐Khan, E., Louzada, M., LeBlanc, R., Sébag, M., Song, K., Jimenez-Zepeda, V. H., Kotb, R. R., Kardjadj, M., et al. (2022) · Current Oncology · doi:10.3390/curroncol29030132 · Cited by 5
Self-citationKaedbey, R., Reece, D. E., Venner, C. P., McCurdy, A. B. R., Su, J., Chu, M. P., Louzada, M., Jimenez-Zepeda, V. H., Mian, H. S., Song, K., et al. (2024) · eJHaem · doi:10.1002/jha2.894 · Cited by 7
“These were the standard of care regimens for many years based on published, phase 3 data from the VISTA [2] and FIRST [3] trials, respectively.”
MethodSelf-citationMunshi, N. C., & Jagannath, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00086-x · Cited by 6
Huang, L., Wong, S. W. K., Andreadis, C. B., & Olin, R. L. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0778-2 · Cited by 7
Isa, R., Uoshima, N., Takahashi, R., Nakano-Akamatsu, S., Kawata, E., Kaneko, H., Shimura, K., Kamitsuji, Y., Takimoto‐Shimomura, T., Mizutani, S., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03859-9 · Cited by 5
“Skin rash was most likely caused by LEN [4, 31], but the underlying cause of the neurologic events in the three patients is unknown.”
BackgroundResultInfluentialOzaki, S., Handa, H., Koiso, H., Saitoh, T., Sunami, K., Ishida, T., Suzuki, K., Narita, T., Iida, S., Nakamura, Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03668-6 · Cited by 5
Advances in biology and therapy
Rajkumar, S. V., & Moreau, P. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.172 · Cited by 5
Self-citationSuzuki, K., Nishiwaki, K., Gunji, T., Katori, M., Masuoka, H., & Yano, S. (2020) · Cancer Medicine · doi:10.1002/cam4.2828 · Cited by 5
Initial Therapy in Older Patients with Multiple Myeloma
Laubach, J. P. (2019) · New England Journal of Medicine · doi:10.1056/nejme1904372 · Cited by 5
Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?
Mian, H. S., Kaiser, M., & Fonseca, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00978-z · Cited by 6
Yang, X., Wang, F., Yuan, X., Yang, B., Chen, J., Cheng, J., Liu, G., Tang, D., Xu, X., Wang, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1466443 · Cited by 4
Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study
Yoon, J., Jung, J., Park, B., Lee, E., Park, Y. S., Yoon, S., & Eom, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13615-0 · Cited by 4
“Rd treatment was continued until disease progression or the occurrence of unacceptable toxicity [11, 12].”
Yadav, R., Chaudary, J. K., Bisht, K., Dhamija, P., Chaudhary, P. K., Nath, U. K., & Jain, N. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152390 · Cited by 7
Molecular and immunological determinants of long-term survival in multiple myeloma
Kasomva, K., Yadav, K., Janz, S., Dhakal, B., & Rao, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016829 · Cited by 4
Vincent, L., Decaux, O., Perrot, A., Royer, B., Chalopin, T., Bobin, A., Macro, M., Caillot, D., Karlin, L., Jacquet, C., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70619 · Cited by 5
Self-citationAn update in treatment options for multiple myeloma in nontransplant eligible patients
Broijl, A., & Sonneveld, P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1075507 · Cited by 4
“Although not head-to-head compared, data in newly diagnosed transplant-ineligible patients are in favor of lenalidomide, generating PFS of 25 -- 31 months [7,8], compared to 14 months (TTF) following bendamustine.”
BackgroundMethodTreatment of Relapsed Myeloma in a Patient With Renal Insufficiency
Bladé, J., Rosiñol, L., Cibeira, M. T., & de Larrea, C. F. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6419 · Cited by 4
Ogiya, D., Murayama, N., Kamiya, Y., Saito, R., Shiraiwa, S., Suzuki, R., Machida, S., Tazume, K., Ando, K., & Yamazaki, H. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04893-w · Cited by 4
Management of Newly Diagnosed Multiple Myeloma Today, and in the Future
Devasia, A. J., Lancman, G., & Stewart, A. K. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.007 · Cited by 4
Ludwig, H., Melchardt, T., Sormann, S., Schreder, M., Andel, J., Hartmann, B. L., Tinchon, C., Zojer, N., Gunsilius, E., Podar, K., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27280 · Cited by 4
Self-citationHuh, C. Y., Park, S., Lee, J. Y., Min, C., Jeon, Y., Yahng, S., & Shin, S. (2024) · Blood Research · doi:10.1007/s44313-024-00025-7 · Cited by 4
“Based on the results of the VISTA [2] and FIRST [3] trials, bortezomib-melpha-lan-prednisolone (VMP) and continuous lenalidomide-dexamethasone (Rd) regimens have emerged as standard treatment options for transplant-ineligible MM [4].”
ResultSelf-citationUp-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma
Abdallah, N. H., & Kumar, S. K. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7039 · Cited by 7
What is the ideal approach—doublet, triplet, or quadruplet(s)?
Kumar, S. K. (2024) · Hematology · doi:10.1182/hematology.2024000581 · Cited by 7
Treatment of elderly and frail myeloma patients
Shih, S. C.-M., Visram, A., & Mian, H. S. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104266 · Cited by 4
Gay, F., Cavallo, F., & Palumbo, A. (2015) · Drugs · doi:10.1007/s40265-015-0367-0 · Cited by 5
“VMP plus thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) was compared with VMP alone.”
InfluentialBonomo, L., Lue, J., Jagannath, S., & Chari, A. (2016) · Cancer Medicine · doi:10.1002/cam4.620 · Cited by 4
“5 MPV [21] No 257 81 24 1 – 87 VTP [18] Yes 130 81 28 25 – 65 VD [17] Yes 168 71 31 NR2 – NR2 VTD [17] Yes 167 79 38 NR2 – NR2 RD [8] Yes 121 – – 25.”
BackgroundManagement of high-risk Myeloma: an evidence-based review of treatment strategies
Lehners, N., Hayden, P. J., Goldschmidt, H., & Raab, M. S. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1204908 · Cited by 4
“In a subgroup analysis of the FIRST trial in transplant-ineligible MM patients, continuous RD did not significantly improve survival compared to MPT in patients with high-risk cytogenetic features, an elevated LDH or severe renal insufficiency [67].”
BackgroundIs Maintenance Therapy for Everyone?
Nooka, A. K., & Lonial, S. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.011 · Cited by 4
Lenalidomide‐based response‐adapted therapy for older adults without high risk myeloma
Baz, R., Naqvi, S. M. H., Lee, J., Brayer, J. B., Hillgruber, N., Fridley, B. L., Shain, K. H., Sullivan, D. M., & Alsina, M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15700 · Cited by 4
“…recently, the Frontline Investigation of Lenalidomide/ Dexamethasone versus Standard Thalidomide trial demonstrated that continuous therapy with lenalidomide and dexamethasone rendered results superior to those of melphalan, prednisone and thalidomide among older adults (Benboubker et al, 2014).”
BackgroundResultInfluentialSelf-citationChen, C. I., Cao, Y., Trudel, S., Reece, D. E., Kukreti, V., Tiedemann, R. E., Prica, A. A., Paul, H. K., Le, L. W., Levina, O., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1747064 · Cited by 4
Self-citationGrant, S. J., Joshi, G., & Lipe, B. C. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.003 · Cited by 4
Kim, S. Y., Park, S., Lim, J., Lee, J. Y., Yoon, J., Lee, S., Eom, K., Kim, H., & Min, C. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.012 · Cited by 4
Self-citationUsing surrogate information to improve confirmatory platform trial with sample size re-estimation
Zhong, C., Li, Q., Wu, L., & Lin, J. (2022) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2022.2080693 · Cited by 4
The treatment of paraprotein-related kidney disease
Hutchison, C. A., Xiong, F., & Mollee, P. N. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000369 · Cited by 4
Ishida, T., Kimura, H., Ozaki, S., Kubo, K., Sunami, K., Takezako, N., Fujita, H., Hayashi, T., Kiguchi, T., Ohashi, K., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03988-6 · Cited by 4
Jansen, L., Merz, M., Engelhardt, M. M., Weisel, K. C., Scheid, C., Straka, C., Langer, C., Salwender, H. J., Einsele, H., Kröger, N. M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1768383 · Cited by 4
Self-citationKlein, C. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-876-3 · Cited by 5
What are the implications of cost for myeloma therapy?
Xu, T., Yang, W., Chen, L., & Gao, G. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1682545 · Cited by 4
“In the past decade, novel agent-based therapies – bortezomib, lenalidomide or thalidomide, and corticosteroid combined regimens – have made contributions to prolonging progression-free survival and the timing of progression in both newly diagnosed MM patients and relapsed or refractory MM patients [10,11].”
BackgroundRanganathan, S., & Prasad, V. K. (2025) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2025.100588 · Cited by 4
Reshaping multiple myeloma treatment: recent breakthroughs
Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2610373 · Cited by 4
“For these reasons, guidelines recommend reducing dexamethasone to 20 mg weekly in patients aged over 75 years [100].”
Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
Horigome, Y., Suzuki, K., & Suzuki, T. (2024) · Life · doi:10.3390/life14030389 · Cited by 4
“On the other hand, while the FIRST trial demonstrated the superiority of Rd over MPT [94,95], the Rd not only delayed the PD compared to the MPT, but also showed clinically meaningful improvements in HRQOL [96].”
ResultHungria, V., Bittencourt, R., Martınez, G., Santos, J. D. A., de Almeida, D. R., Figueiredo, V., de Farias, D. L. C., Zanella, K. R., Muniz, L. B., Senra, J., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.002 · Cited by 4
Richter, J. R., Nooka, A. K., Rodríguez‐Otero, P., Schjesvold, F. H., Katodritou, E., Combe, E., Scott, M., Cooper, L., Sly, I., Ballew, N., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27661 · Cited by 3
[Advances on immunomodulatory drugs against multiple myeloma].
Wang, S., & Jin, F. (2016) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2016.03.021 · Cited by 3
“[14] Benboubker L, Dimopoulos MA, Dispenzieri A, et al.”
BackgroundCarfilzomib in Combination with Daratumumab in the Management of Relapsed Multiple Myeloma
Touzeau, C., Antier, C., & Moreau, P. (2020) · Future Oncology · doi:10.2217/fon-2020-0907 · Cited by 3
Self-citationHu, S.-L., Liu, M., & Zhang, J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i32.11712 · Cited by 3
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Schey, S., Montero, L. F. C., Stengel-Tosetti, C., Gibson, C. J., & Dhanasiri, S. (2017) · Oncology and Therapy · doi:10.1007/s40487-016-0037-8 · Cited by 3
“Thalidomide 7 14 17 4 21 36 Bortezomib 37 25 71 30 13 58 Lenalidomide 56 61 12 66 66 6 BORT bortezomib, LEN lenalidomide, THAL thalidomide a Pomalidomide-based regimens assumed to be used exclusively after third line; some patients were assumed to receive a re-treatment, e.g., MPT after first-line MPT Table 4 Market s…”
BackgroundInfluentialSharpley, F. A., Djebbari, F., Fourali, S., Kothari, J., Lynes, J. A., McLain-Smith, S., & Ramasamy, K. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1683737 · Cited by 3
“MPT.”
BackgroundMethodResultInfluentialBelch, A. R., Bahlis, N. J., White, D. J., Cheung, M. C., Chen, C. I., Shustik, C., Song, K., Tosikyan, A., Dispenzieri, A. A., Anderson, K. C., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3511 · Cited by 3
Self-citationAnti-body building: The exercise of advancing immune based myeloma therapies
Richter, J. R., & Thibaud, S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100789 · Cited by 3
Zagouri, F., Ρούσσου, Μ., Kastritis, E., Gavriatopoulou, M., Eleutherakis‐Papaiakovou, E., Kanellias, N., Kalapanida, D., Christoulas, D., Migkou, M., Terpos, E., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1151513 · Cited by 4
“autologous stem-cell transplantation.[4,5] Currently,”
Self-citationCavo, M. (2016) · Blood · doi:10.1182/blood-2015-11-678524 · Cited by 3
Self-citationGassiot, S., Motlló, C., Llombart, I., Morgades, M., González, Y., García-Caro, M., Ribera, J., & Oriol, A. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12869 · Cited by 3
“Creatinine >2 mg/dl, n (%) 18 (12) 14 (16) 4 (6) p=.”
Self-citationStrategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients
Steinbach, M. N., Richards, T. A., & Faiman, B. M. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.003 · Cited by 5
Diagnostik und Therapie des Multiplen Myeloms
Baertsch, M., & Goldschmidt, H. (2017) · Info Onkologie · doi:10.1007/s15004-017-5561-7 · Cited by 3
“Dabei werden vor allem das auf eine begrenzte ¥erapiedauer angelegte VMP (Borte zomib/Melphalan/Prednison)-Schema [18] und das kontinuierliche Rd(Lenalidomid/Dexamethason)-Schema [19] angewendet.”
BackgroundLund, J., Gruber, A., Lauri, B., Duru, A. D., Blimark, C. H., Swedin, A., Hansson, M., Forsberg, K., Ahlberg, L., Carlsson, C., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1422 · Cited by 2
“The 3- year PFS rate with continued Len+Dex was ~40% [22].”
BackgroundManier, S., de la Contrie, M. D. C., Hieulle, J., Daniel, A., & Facon, T. T. F. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.07.023 · Cited by 7
Self-citationTakezako, N., Kosugi, H., Matsumoto, M., Iida, S., Ishikawa, T., Kondo, Y., Ando, K., Miki, H., Matsumura, I., Sunami, K., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02953-3 · Cited by 3
Rampotas, A., Djebbari, F., Panitsas, F. P., Lees, C., Tsagkaraki, I., Gomes, A. R., Prideaux, S., Chen, L., Prodger, C. F., Khera, A., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13588 · Cited by 3
“High- risk cytogenetics is defined as one or more of the following features: t(4;14), t (14;16), del(17p), t(14;20), 1q gain.”
BackgroundMethodSaleh, A. S. A., Visram, A., Parmar, H. V., Muchtar, E., Buadi, F. K., Dispenzieri, A. A., Warsame, R. M., Lacy, M. Q., Dingli, D., Leung, N., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1950708 · Cited by 3
“Major regimens tested in clinical trials for elderly non-transplant eligible MM patients include Rd [1], bortezomib, melphalan, and prednisone (VMP) [2], daratumumab, lenalidomide, and dexamethasone (DRd) [3], and daratumumab, bortezomib, melphalan, and prednisone (DVMP) [4].”
Self-citationSandecká, V., Pour, L., Špıčka, I., Minařík, J., Radocha, J., Jelínek, T., Heindorfer, A., Pavlíček, P., Sýkora, M., Jungová, A., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13683 · Cited by 3
Management of Multiple Myeloma in Older Patients
Li, J., & Chan, H. S. H. (2021) · EMJ Hematology · doi:10.33590/emjhematol/20-00241 · Cited by 4
Multiple Myeloma: Current Advances and Future Directions
Murakami, H. (2020) · The Kitakanto Medical Journal · doi:10.2974/kmj.70.175 · Cited by 3
Wang, Y., Liu, Y., Jin, S., Yi, T., Zhang, W., Chen, J., Jiang, S., & Mi, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-91126-5 · Cited by 2
“An increased focus on continuous therapy 4,5 has heightened the need for regimens that have acceptable side-effect profiles and that are easy to administer.”
Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers
Wong, E. C., Staskiewicz, A., Pruner, J., Lee, J. Y. H., Tucker, M., Smith, B., Rogers, L. J., Asuni, G., & Wang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1589090 · Cited by 2
Self-citationBringhen, S., Cani, L., Antonioli, E., Derudas, D., Fazio, F., Larocca, A., Ronconi, S., Cellini, C., Falcone, A. P., Accardi, F., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00162-0 · Cited by 4
Treatment of transplant-ineligible multiple myeloma
Jung, J. (2025) · Blood Research · doi:10.1007/s44313-025-00102-5 · Cited by 3
“This regimen demonstrated significantly better PFS than the group that received Rd for 18 cycles followed by discontinuation (Rd18) and the group treated with MPT (median 25.5 vs. 20.7 vs. 21.2 months, p 0.001) [15].”
InfluentialYang, X. W., Wang, P., Xu, T., Yu, C., Yang, Y., & Liu, P. (2025) · Hematological Oncology · doi:10.1002/hon.70156 · Cited by 2
Filho, J. T. D. S., Cantadori, L. O., Crusoé, E. D. Q., Hungria, V., & Maiolino, Â. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01413-7 · Cited by 7
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
Neupane, K., Singstock, M., Shah, D., Dahal, R., Mian, H. S., Smith, F., Chakraborty, R., Hadidi, S. S. A. A., Mainou, M., Grajales-Cruz, A. F., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70323 · Cited by 3
“11”
Sugi, T., Mita, M., Yasu, T., Kubo, K., Kushi, R., Hanai, H., Ohara, S., Uchida, T., Inoue, M., & Hagihara, M. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13568 · Cited by 4
Bagot, J.-L. (2022) · OBM Integrative and Complementary Medicine · doi:10.21926/obm.icm.2203026 · Cited by 2
Recent Updates on Multiple Myeloma
Al-Anazi, K. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100849 · Cited by 2
Xu, T., Yang, Y., Li, J., Xu, J., Wang, W., Wang, Y., Maihemaiti, A., Ren, L., Lan, T., Zhou, C., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05148-y · Cited by 2
“As far as lenalidomide maintenance is concerned, although lenalidomide is the standard of care for maintenance in most patients [4–7] and shows significant improvement in PFS and OS in a meta-analysis in the transplant setting [10], the evidence in non-transplant setting is still relatively lacking [7, 13, 23], and ea…”
BackgroundMoustafa, M. A., Parrondo, R. D., Abdulazeez, M. F., Roy, V., Sher, T., Alegria, V. R., Warsame, R. M., Fonseca, R., Rasheed, A., Gonsalves, W. I., et al. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001520 · Cited by 2
Xie, D., & Zhang, P.-F. (2025) · BMJ Open · doi:10.1136/bmjopen-2023-076914 · Cited by 2
Zilu, M., Zheng, H., Li, Y., Bai, J., Zhang, L., & Li, L. (2025) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2025.101202 · Cited by 3
Current Treatment Approaches to Multiple Myeloma with New Agents
Maral, S., Albayrak, M., & Pala, Ç. (2018) · Journal of Clinical and Experimental Investigations · doi:10.5799/jcei.433823 · Cited by 2
“Toplam 1623 ileri yaş hastanın dahil edildiği FIRST çalışmasında, kesintisiz lenalidomid-deksametazon alan hastaların toplam 12 siklus melfalan-talidomid alan hastalara kıyasla progresyon ve ölüm riskinde %31 azalma ve toplam sağ kalımda 10 aylık üstünlüğe sahip olduğu bildirilmiştir [44].”
Metadata
- Authors
- Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., & Facon, T.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- University of Alberta (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Universitair Ziekenhuis Leuven (BE)
- St Bartholomew's Hospital (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Dalhousie University (CA)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Hôpital Purpan (FR)
- Celgene (United States) (US)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- ORCID
- Benboubker, Lotfi
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew R.
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar
- Banos, Anne
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- Qiu, Lugui
- White, Darrell J.
- Anderson, Kenneth
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Jacques, Christian
- Hulin, Cyrille
- Facon, Thierry
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-04
- Volume
- 371
- Issue
- 10
- Pages
- 906-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141105112
- Cited by
- 793
- References
- 38
- Citations by year
- 2026: 18 · 2025: 41 · 2024: 39 · 2023: 37 · 2022: 54 · 2021: 74 · 2020: 89 · 2019: 75 · 2018: 80 · 2017: 92 · 2016: 102 · 2015: 76 · 2014: 15
- FWCI
- 67.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, dexamethasone, multiple myeloma, transplant-ineligible patients, progression-free survival, overall survival, treatment duration, adverse events, second primary malignancy, infection, neurotoxicity, hematologic toxicity, newly diagnosed multiple myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.